Psoriatic Arthritis Linked to Pembrolizumab in a Lung Cancer Patient: From Oncologist to Rheumatologist
Mihaela-Maria Pasca Fenesan, Elena Sirbu, Andreea Iana
TL;DR
A lung cancer patient developed psoriatic arthritis after receiving pembrolizumab, highlighting the challenges of managing such immune-related side effects.
Contribution
This case report highlights psoriatic arthritis as a rare immune-related adverse effect of pembrolizumab in lung cancer patients.
Findings
A 69-year-old male developed psoriatic arthritis after pembrolizumab treatment for lung cancer.
The case emphasizes the challenges in managing immune-related rheumatic adverse effects in oncology patients.
Abstract
Immune-related rheumatic adverse effects (rheumatic IAEs) are commonly observed in patients undergoing immunotherapy for solid tumors and hematologic malignancies. The Romanian National Health Insurance House offers all patients free access to oncology medications and has significantly improved in recent years. Here, we present a case of a 69-year-old male patient diagnosed with a bronchopulmonary neoplasm who developed psoriatic arthritis (PsA) after receiving immunotherapy with pembrolizumab, emphasizing the challenges of therapeutic management in this case.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCancer Immunotherapy and Biomarkers · Colorectal Cancer Treatments and Studies · Chronic Lymphocytic Leukemia Research